Holland Capital is a private equity firm that focuses on value creation in venture, growth, and buy-out investments.

Bart Howe

Holland Capital

Crossings Capital specializes in capital raising and capital restructuring services for businesses. self-described.

Crossings Capital

Granaria is a globally operating investment company, self-described as having a century of experience.

Granaria

Holland Capital has been responsibly and successfully investing in promising Dutch and German SMEs with growth ambitions for over 40 years. The team understands entrepreneurship and fosters an open, sustainable, and professional relationship with the management teams of the invested companies, aiming for mutual growth. With offices in Amsterdam and Düsseldorf, Holland Capital focuses on Healthcare, Technology, and the Agrifood-Tech sector. 

Magnum Technologies

Opdidakt

Virtual Affairs

IQ Messenger

BlueCielo

BWise

Autheos

Avensus

Cytosmart

Esdec BV

Freecom

Purple

QSight IT

Quantib

Our portfolio company Magnus Energy and Ciratum | Business en IT consultants have joined forces. This acquisition marks a significant step towards Magnus Energy’s ambition of establishing a pan-European consulting firm dedicated to supporting the energy transition.

https://lnkd.in/eVK4sHnV

Alexander van der Mark, Rudolf Das
Ewout Prins, Laurens Platteeuw, Hidde van der Gaag

#buyandbuild #portfoliocompany #magnusenergy #ciratum

uman, the Belgium-based AI-driven software platform for B2B sales teams, raises 1.9 million euros. The funding round is led by Holland Capital, together with existing investors imec and Seeder Fund.

https://lnkd.in/eVGEAxv8

Charles Boutens, Sven Degroote, Jorg Van Der Heijden, Thomas Batsleer, Wouter Gerritsen.

#uman #growthinvestment #venturecapital

"Investing in scale-ups requires vision, expertise, and courage. And that's just the beginning." Discover the insightful questions that Jan-Frens van Giessel - our Partner Venture & Growth Healthcare - tackles daily to maximize organizational potential. Dive into our exclusive interview to gain valuable perspectives.

Explore the full interview here: https://ap.lc/IBCkO


#hollandcapitalteam
#growthbuyout
#venturegrowth
#HCsofasessions

We are proud to announce the successful exit of Defibrion to IK Partners. 
Since 2019, Defibrion's management team has successfully collaborated with Holland Capital.

https://lnkd.in/e7sERmdq

Joshua Valkenier, Marijn Silvis, Axel Jongert, Ewout Prins

#healthcare #exitnews #defibrion

25Friday, Holland Capital , Endeit Capital and Mediahuis Ventures are hosting a Product Roadmapping roundtable for all CEOs, Product leaders, and enthusiasts in your team! 
 
Forward this as an invite to your product leaders and enthusiasts if deemed relevant! 📨
 
Here are the most important event details 👇

Date: Thursday, April 18th
Program: 15:30 walk-in, 16:00 start, 17:00 end & networking (optional)
Location: Edge Olympic (Fred. Roeskestraat 115 - 317, 1076 EE Amsterdam)

Join us for a dynamic session on product roadmapping designed for SaaS/tech scale-ups.

Here are the topics we will cover:
  🎯Aligning your product vision with the company vision & mission
  📈Setting Objectives & Key Results (OKRs)
  ⚖️Unbiased prioritization with the value-effort quadrant
  🗺️ Turning priorities into actionable roadmaps
  👋 Concluding insights and takeaways

You can register via this link:  https://bit.ly/3TyfIo6 

❗P.S.: We only have 35 seats available, so quick registration would be best. The event will take place at the office of 25Friday (Edge Olympic - Fred Roeskestraat 115, Amsterdam).
 
 
 
#Roadmapping #ProductDevelopment #TechInnovation #SaaS #TechScaleUp #25Friday

At Holland Capital, we regularly welcome talented interns who want to take their first steps into the world of private equity and venture capital. Thom Craanen completed his internship at Holland Capital and we are proud to add him to our Technology and Agrifood teams as a Investment Analyst. 

Want to know more about Thom's internship? Read the interview in which Thom shares his experiences and insights on what made this internship so special for him.

https://ap.lc/cPyeT

#hollandcapital #internship #growthbuyout #Investmentanalyst

Metric
Company Name	Holland Capital	Crossings Capital	Granaria
Symbol
MSH ID	NL:HOLLANDCAPITAL	COM:CROSSINGS-CAPITAL	NL:GRANARIA
Market	PRIVATE	PRIVATE	PRIVATE
Sector	Financial Services & Finance	Financial Services & Finance	Financial Services & Finance
Industry	Private Equity	Investment Services	Investment Management
Country	NL	NL	NL
Stage
Employee Count	52
Website	hollandcapital.nl	crossings-capital.com	granaria.nl
LinkedIn	hollandcapital
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

HOLL

NL:HOLLANDCAPITAL

Holland Capital

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue